Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

NeuroPace, Inc. (NPCE)

1.61   0.06 (3.87%) 11-25 13:00
Open: 1.66 Pre. Close: 1.55
High: 1.895 Low: 1.6001
Volume: 42,921 Market Cap: 40(M)

Technical analysis

as of: 2022-11-25 1:59:07 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.03     One year: 3.91
Support: Support1: 1.37    Support2: 1.14
Resistance: Resistance1: 2.59    Resistance2: 3.34
Pivot: 1.85
Moving Average: MA(5): 1.52     MA(20): 2.06
MA(100): 3.95     MA(250): 6.24
MACD: MACD(12,26): -0.5     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 11.9     %D(3): 9
RSI: RSI(14): 28
52-week: High: 12.06  Low: 1.37
Average Vol(K): 3-Month: 67 (K)  10-Days: 271 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NPCE ] has closed above bottom band by 32.4%. Bollinger Bands are 15.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.56 - 1.57 1.57 - 1.58
Low: 1.49 - 1.5 1.5 - 1.51
Close: 1.53 - 1.55 1.55 - 1.57

Company Description

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Headline News

Thu, 24 Nov 2022
Massive Insider Trade At NeuroPace - NeuroPace (NASDAQ:NPCE) - Benzinga

Wed, 23 Nov 2022
Accelmed Partners Increases Position in Neuropace (NPCE) - Nasdaq

Mon, 21 Nov 2022
Healthcare Stocks Lead 52-Week Lows Monday; Markets Mixed - InvestorsObserver

Thu, 17 Nov 2022
Neuropace Inc (NPCE) Stock: What Does the Chart Say Thursday? - InvestorsObserver

Sat, 12 Nov 2022
Neuropace, Inc. (NPCE) Q3 2022 Earnings Call Transcript - Seeking Alpha

Tue, 08 Nov 2022
2022-11-08 | NDAQ:NPCE | Press Release | Neuropace Inc. - Stockhouse

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. 25 (M)
Shares Float 7 (M)
% Held by Insiders 13.2 (%)
% Held by Institutions 89.4 (%)
Shares Short 613 (K)
Shares Short P.Month 618 (K)

Stock Financials

EPS -1.72
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.75
Profit Margin (%) -106.7
Operating Margin (%) -91.4
Return on Assets (ttm) -19.1
Return on Equity (ttm) -74.6
Qtrly Rev. Growth 7.9
Gross Profit (p.s.) 1.34
Sales Per Share 1.75
EBITDA (p.s.) -1.6
Qtrly Earnings Growth 0
Operating Cash Flow -37 (M)
Levered Free Cash Flow -21 (M)

Stock Valuations

PE Ratio -0.95
PEG Ratio 0
Price to Book value 0.92
Price to Sales 0.91
Price to Cash Flow -1.08

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.